Vasculitis Trial, Recruiting (NCT07037732)

Vasculitis Trial, Recruiting NCT07037732 Sponsor: Centre Hospitalier Universitaire de Nice Condition: Vasculitis

Printed from Voxsanity (voxsanity.com.au) — NCT07037732 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Vasculitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You are already receiving a medication called rituximab as part of your normal medical care (not as part of a study).
You have been diagnosed with one of the following conditions: a blood platelet disorder called immune thrombocytopenia, a condition where the immune system destroys red blood cells (autoimmune hemolytic anemia), lupus (systemic lupus erythematosus), systemic sclerosis (a connective tissue disease), rheumatoid arthritis, inflammatory muscle disease (inflammatory myopathy), a type of blood vessel inflammation called ANCA-associated vasculitis, or another type of blood vessel inflammation called cryoglobulinemic vasculitis.

Who may not be able to join:

You are taking several immune-suppressing medications at the same time because your condition has been difficult to treat, or because you also have a blood disorder or cancer.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 04.92.03.54.44

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07037732

Sponsor: Centre Hospitalier Universitaire de Nice

Phase: Not Applicable

Status: Recruiting

Condition: Vasculitis

Trial contact: 04.92.03.54.44

More information: https://clinicaltrials.gov/study/NCT07037732

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You are already receiving a medication called rituximab as part of your normal medical care (not as part of a study).
You have been diagnosed with one of the following conditions: a blood platelet disorder called immune thrombocytopenia, a condition where the immune system destroys red blood cells (autoimmune hemolytic anemia), lupus (systemic lupus erythematosus), systemic sclerosis (a connective tissue disease), rheumatoid arthritis, inflammatory muscle disease (inflammatory myopathy), a type of blood vessel inflammation called ANCA-associated vasculitis, or another type of blood vessel inflammation called cryoglobulinemic vasculitis.

Who may not be able to join:

You are taking several immune-suppressing medications at the same time because your condition has been difficult to treat, or because you also have a blood disorder or cancer.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Centre Hospitalier Universitaire de Nice

Registry

ClinicalTrials.gov

Start date

1 June 2025

Est. completion

1 January 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Patients with (Immune Thrombocytopenia) ITP; Patients with AIHA Autoimmune Hemolytic Anemia.; Patients with inflammatory myopathy; Patients with systemic lupus erythematous :; Patients with systemic vasculitis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov